NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,897 | +3.5% | 11,580 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $6,661 | -45.5% | 11,580 | -33.3% | 0.00% | -50.0% |
| Q1 2023 | $12,211 | -68.9% | 17,370 | 0.0% | 0.00% | -71.4% |
| Q4 2022 | $39,256 | -29.9% | 17,370 | 0.0% | 0.01% | -41.7% |
| Q3 2022 | $56,000 | -15.2% | 17,370 | 0.0% | 0.01% | -14.3% |
| Q2 2022 | $66,000 | -29.8% | 17,370 | 0.0% | 0.01% | -12.5% |
| Q1 2022 | $94,000 | -60.0% | 17,370 | 0.0% | 0.02% | -61.0% |
| Q4 2021 | $235,000 | -24.7% | 17,370 | 0.0% | 0.04% | -18.0% |
| Q3 2021 | $312,000 | +4.7% | 17,370 | 0.0% | 0.05% | +6.4% |
| Q2 2021 | $298,000 | -33.3% | 17,370 | -25.0% | 0.05% | -39.7% |
| Q1 2021 | $447,000 | +13.5% | 23,160 | 0.0% | 0.08% | +27.9% |
| Q4 2020 | $394,000 | +2.6% | 23,160 | 0.0% | 0.06% | -17.6% |
| Q3 2020 | $384,000 | – | 23,160 | +115700.0% | 0.07% | – |
| Q2 2020 | $0 | – | 20 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |